Schöttle, Daniel http://orcid.org/0000-0002-8589-727X
Janetzky, Wolfgang
Luedecke, Daniel
Beck, Elmar
Correll, Christoph U.
Wiedemann, Klaus
Funding for this research was provided by:
Otsuka GmbH, Frankfurt, Germany and Lundbeck GmbH, Hamburg, Germany
Article History
Received: 19 July 2018
Accepted: 30 October 2018
First Online: 14 November 2018
Change Date: 14 December 2018
Change Type: Correction
Change Details: Following publication of the original article
Ethics approval and consent to participate
: This study was approved by the Freiburg ethics commission international (Approval number: 014/1336). All patients gave written informed consent.Planning, conduct and evaluation of the NIS was based on legal requirements of the German Medical Products Act (Gesetz über den Verkehr mit Arzneimitteln, §4 (23), sentence 3), the relevant recommendations of the Federal Institute for Drugs and Medical Devices (BfArM) and the Paul-Ehrlich Institute (Empfehlungen des Bundesinstituts für Arzneimittel und Medizinprodukte und des Paul-Ehrlich-Instituts zur Planung, Durchführung und Auswertung von Anwendungsbeobachtungen 2010) as well as the guidelines of the FSA code (Freiwillige Selbstkontrolle für die Arzneimittelindustrie e. V. 2015).
: Not applicable.
: DS received honoraria for lectures from Janssen GmbH, Lundbeck GmbH and Otsuka Pharma GmbH, WJ is an employee of Lundbeck GmbH, DL and EB reported no conflicts of interest, CC has been a consultant and/or advisor to or has received honoraria from: Alkermes, Allergan, Gerson Lehrman Group, IntraCellular Therapies, Janssen/J&J, LB Pharma, Lundbeck, Medavante, Medscape, Neurocrine, Otsuka, Pfizer, ROVI, Sunovion, Takeda, and Teva. He has provided expert testimony for Bristol-Myers Squibb, Janssen, and Otsuka. He served on a Data Safety Monitoring Board for Lundbeck, Pfizer, Roche, and ROVI. He received royalties from UpToDate and grant support from Janssen, Neurocrine and Takeda. He is also a shareholder of LB Pharma, KW has been a consultant and received honoraria for lectures from Janssen GmbH, Lundbeck GmbH and Otsuka Pharma GmbH.
: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.